Michael Neu,Markus Tschoepe,Carsten Weber,Wolfgang Fraunhofer,Laura Redden,Martin Gastens,Alexander Feick,Susan K. Paulson,Tong Zhu
申请号：
US16101349
公开号：
US20190211093A1
申请日:
2018.08.10
申请国别(地区):
US
年份:
2019
代理人:
摘要：
The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof.
